Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Pulmatrix Inc    PULM

 SummaryQuotesChartsNewsCalendarCompany 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/18/2017 09/19/2017 09/20/2017 09/21/2017 09/22/2017 Date
1.95(c) 2.01(c) 2.0914(c) 2.04(c) 2.01(c) Last
553 492 1 544 768 2 313 486 367 773 257 440 Volume
+9.55% +3.08% +4.05% -2.46% -1.47% Change
More quotes
Company
Pulmatrix, Inc. is a clinical stage biotechnology company, which is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs.It designs and develops inhaled therapeutic... 
Sector
Biotechnology & Medical Research
Calendar

- No events available -

More about the company
Latest news on PULMATRIX INC
09/21 PULMATRIX : to Present at the Cantor Fitzgerald Global Healthcare Conference on ..
09/21 PULMATRIX : Receives Key Patents on its Inhaled Drug Delivery Technology and its..
09/20 PULMATRIX : CEO Robert Clarke Discusses Positive Developments from Partnerships ..
09/20 PULMATRIX : Receives Key Patents on its Inhaled Drug Delivery Technology and its..
09/19 CEO Robert Clarke Discusses Positive Developments from Partnerships Obtained ..
09/14 PULMATRIX : Licenses Inhaled COPD Drug PUR0200 to Vectura Group plc
09/14 PULMATRIX : to Present at the Rodman & Renshaw Global Investment Conference on S..
09/11 PULMATRIX, INC. (NASDAQ : PULM) Files An 8-K Regulation FD Disclosure
09/11 PULMATRIX, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (f..
09/08 PULMATRIX : to Present at the Rodman & Renshaw Global Investment Conference on S..
More news
Sector news : Bio Therapeutic Drugs
09/20DJSANOFI : Alnylam Report Positive Patisiran Phase III Trial, First-Ever for RNAi ..
09/15 Drug industry on tenterhooks as Maryland price-gouging law nears
09/07 New AstraZeneca, Amgen drug looks strong rival in severe asthma
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag -- Update
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag
More sector news : Bio Therapeutic Drugs
Latest Tweets
09/22Pulmatrix to Present at the Cantor Fitzgerald Global Healthcare Conference on.. 
09/20Algo ? $SPN $SWN $PULM $HMNY $CVE $MRTX $FENG $TAHO Charts @  
09/20Pulmatrix nabs two U.S. patents covering iSPERSE technology and PUR0200; shar.. 
09/20$PULM: Pulmatrix announces that it has received two important new patents fro..
1
09/20Pulmatrix Receives Key Patents on its Inhaled Drug Delivery Technology and it.. 
More tweets
Qtime:16
News from SeekingAlpha
09/20 Pulmatrix nabs two U.S. patents covering iSPERSE technology and PUR0200; shar..
09/19 After Hours Gainers / Losers
09/19 Pulmatrix CEO bullish on pipeline; shares ahead 9%
09/18 PULMATRIX : The Best Biotech Buyout Target Out There?
09/06 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
Chart PULMATRIX INC
Duration : Period :
Pulmatrix Inc Technical Analysis Chart | PULM | US74584P1030 | 4-Traders
Technical analysis trends PULMATRIX INC
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Managers
NameTitle
Robert W. Clarke President, Chief Executive Officer & Director
Mark T. Iwicki Chairman
William E. Duke Chief Financial Officer, Treasurer & Secretary
David L. Hava Chief Scientific Officer
Terrance G. McGuire Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PULMATRIX INC254.47%40
AMGEN28.70%136 186
CELGENE CORPORATION24.61%112 486
GILEAD SCIENCES15.40%107 896
REGENERON PHARMACEUTICALS19.36%46 445
VERTEX PHARMACEUTICALS107.30%38 337